Platelet-rich Plasma for Chronic Lateral Ankle Instability

April 2, 2019 updated by: Pei-Yuan Lee, MD

Efficacy of Platelet-rich Plasma in the Treatment of Chronic Lateral Ankle Instability

This study aims to evaluate the effect of platelet-rich plasma (PRP) on chronic lateral ankle instability by comparing the imaging and clinical outcomes between patients receiving PRP and those receiving whole blood during the modified Broström-Gould procedure.

Study Overview

Detailed Description

Chronic lateral ankle instability (CAI) in a common foot and ankle problem. It has been linked to recurrent ankle pain, swelling, and even early degenerative change if not properly treated. Lateral ligament reconstruction using modified Broström-Gould procedure is the mainstream in treatment of CAI. Early mobilization is related to better functional outcome, and rapid healing of the repair is the key point to shorten the immobilization time. Platelet-rich plasma (PRP) is a fraction of plasma that contains platelets and multiple growth factors concentrated at high level. Because activated platelets have the potential to release growth factors, PRP has been clinically used to accelerate wound healing and tissue regeneration. However, there is no conclusion regarding the efficacy of PRP on CAI. This clinical trial will investigate the effect of PRP on CAI. Eligible patients will be randomly assigned to receive PRP or whole blood during the modified Broström-Gould procedure. The postoperative imaging and clinical outcomes will be compared and analyzed.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Changhua
      • Changhua City, Changhua, Taiwan, 500
        • Show Chwan Memorial Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 60 years (ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 20 and 60 years
  • With diagnosis of chronic lateral ankle instability

Exclusion Criteria:

  • Poor controlled diabetes
  • Peripheral artery obstructive disease
  • Skin or soft tissue infection at ankle
  • With current or prior history of ankle disease, including degeneration arthritis, fracture, deformity, and cartilage disease.
  • With prior history of ankle surgery
  • With current or prior history of cancer
  • With current or prior history of hematological disease
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: PRP group
15 patients will receive platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
PLACEBO_COMPARATOR: Control group
15 patients will receive whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament.
Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3-month postoperative ankle function evaluated by AOFAS Ankle-Hindfoot score
Time Frame: 3-month postoperative
Ankle function is evaluated by AOFAS Ankle-Hindfoot score
3-month postoperative

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3-month postoperative ankle pain evaluated by visual analogue scale
Time Frame: 3-month postoperative
Ankle pain is evaluated by visual analogue scale
3-month postoperative
3-month postoperative anterior displacement of ankle evaluated by stress radiographs of anterior drawer test
Time Frame: 3-month postoperative
Anterior displacement is evaluated by the anterior displacement of the talus relative to the tibia on stress radiographs of anterior drawer test.
3-month postoperative
3-month postoperative lateral tilt of ankle evaluated by stress radiographs of talar tilt test
Time Frame: 3-month postoperative
Lateral tilt of ankle is evaluated by stress radiographs of talar tilt test.
3-month postoperative
Percentage of patients with healed ligament evaluated by MRI
Time Frame: 3-month postoperative
Healing condition of ligament is assessed by MRI.
3-month postoperative
Percentage of patients with healed ligament evaluated by second look arthroscopy
Time Frame: 3-month postoperative
Healing condition of ligament is assessed by second look arthroscopy.
3-month postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 5, 2016

Primary Completion (ACTUAL)

January 12, 2019

Study Completion (ACTUAL)

January 31, 2019

Study Registration Dates

First Submitted

April 13, 2017

First Submitted That Met QC Criteria

June 21, 2017

First Posted (ACTUAL)

June 23, 2017

Study Record Updates

Last Update Posted (ACTUAL)

April 4, 2019

Last Update Submitted That Met QC Criteria

April 2, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • RA-16026-RD-105066

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Platelet-rich Plasma

Clinical Trials on Platelet-rich plasma

3
Subscribe